Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
90 participants
OBSERVATIONAL
2023-03-01
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
•is there a specific pattern of brain metabolism in patients with autoimmune encephalitis Participants data and images will be retrospectively collected from hospital records, and FDG-PET images will be analyzed by means of statistical parametric mapping (SPM). Controls will be selected from validated public databases.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
NCT06079294
Neuroinflammatory PET Imaging in Autoimmune Encephalomyelitis
NCT05293405
Study of Cerebral Glucose Metabolism in Healthy Volunteers Using 18 F-FDG PET: Evaluation of the Effects of Aging, Comparative Evaluation of Neurodegenerative and Psychiatric Pathologies.
NCT06164938
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
NCT06432803
Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA
NCT03409913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autoimmune Encephalitis patients
Patients with autoimmune encephalitis admitted to the centers, who underwent a brain FDG-PET during the course of their disease trajectory.
FDG-PET
Brain FDG-PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDG-PET
Brain FDG-PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Brain magnetic resonance imaging performed between clinical presentation and treatment
* Cerebrospinal fluid analysis performed between clinical presentation and treatment
* Brain FDG-PET performed between clinical presentation and treatment
* Autoantibodies testing performed between clinical presentation and treatment
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Milano Bicocca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simone Beretta, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Milano Bicocca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Sanitaria Universitaria Friuli Centrale
Udine, Friuli Venezia Giulia, Italy
IRCCS Ospedale Policlinico San Martino
Genoa, Liguria, Italy
Fondazione IRCCS Mondino
Pavia, Lombardy, Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, Monza E Della Brianza, Italy
Fondazione IRCCS Istituto Neurologico "Carlo Besta"
Milan, , Italy
Ospedale San Paolo
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Francesco Deleo, MD, PhD
Role: primary
Francesco Del Sole, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.